Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
AdBio Partners is a venture capital firm based in Europe, formerly known as Advent France Biotechnology. The firm specializes in early-stage investments in life sciences companies, managing a portfolio of 13 companies. It collaborates with leading research institutions and technology transfer offices to catalyze the creation of startups based on academic innovations.
AdBio Partners invests in early-stage life sciences startups, targeting therapeutic areas such as oncology, immunology, ophthalmology, and rare diseases. The firm typically engages in pre-seed to Series A funding rounds, supporting projects that aim to deliver first- or best-in-class products addressing significant medical needs.
Notable companies in AdBio Partners' portfolio include Alderaan Biotechnology, AndzonBio1, AndzonBio2, Agomab Therapeutics, ARTHEx Biotech, Augustine Therapeutics, Depth Charge Therapeutics, DiogenX, Integra Therapeutics, SparingVision, Thabor Therapeutics, Urania Therapeutics, and Yukin Therapeutics, each focusing on innovative therapeutic solutions.
Submit your pitch through their form at adbio.partners or email contact@adbio.partners with your deck.
Yes, AdBio Partners often leads funding rounds in the early stages of investment, particularly in pre-seed and seed rounds.
The firm is open to follow-on investments, especially for companies that demonstrate significant progress and potential in their therapeutic developments.
Specific details about the size of AdBio Partners' current fund are not publicly disclosed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.